Search - tctmd.com

Displaying 61 - 80 of 163

Sort: Relevancy | Date

News Conference News HFSA 2023

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

Shelley Wood

October 13, 2023

News Conference News ESC 2023

ESC Cardiomyopathy Guidelines Span Range of Phenotypes

Yael L. Maxwell

August 31, 2023

News Opinion Editor's Corner ESC 2023

What’s Going to Be Hot at ESC 2023?

Shelley Wood

August 15, 2023

News Conference News ESC Heart Failure 2023

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

Shelley Wood

May 25, 2023

News Conference News ESC Heart Failure 2023

Loop Diuretics Are Heavily Prescribed Outside of HF: That’s a Problem

Shelley Wood

May 23, 2023

News Conference News ACC 2023

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

Michael O'Riordan

March 07, 2023

News Daily News

Top Heart Failure News of 2022

Shelley Wood

January 04, 2023

News Features

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

Shelley Wood

December 20, 2022

News Daily News

AI Accurately Detects LV Dysfunction Using Single-Lead Apple Watch ECG

Todd Neale

November 17, 2022

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

News Daily News

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Todd Neale

September 15, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Conference News ESC 2022

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

Shelley Wood

August 27, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

Advertisement

Survey Offers Clues to Waning Appeal of Acute HF/Transplant Fellowships

ESC Cardiomyopathy Guidelines Span Range of Phenotypes

What’s Going to Be Hot at ESC 2023?

Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues

Loop Diuretics Are Heavily Prescribed Outside of HF: That’s a Problem

Studies Support (Careful) Return to Sport for Athletes With Genetic Conditions

Top Heart Failure News of 2022

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

AI Accurately Detects LV Dysfunction Using Single-Lead Apple Watch ECG

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

TCTMD’s Top 10 Most Popular Stories for April 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content